Injection of Mitomycin-C in Nasolacrimal Duct for Treatment of Partial Nasolacrimal Duct Obstruction

To determine the safety and efficacy of mitomycin-C injection into the lacrimal duct for treatment of partial nasolacrimal duct obstruction in adults. This is a before-after clinical trial performed on 20 patients with partial primary acquired nasolacrimal duct obstruction. We injected 1.5 ml of mitomycin-C 0.2 mg/ml into the lacrimal duct and repeated it with concentration of 0.3 mg/ml for inadequate response. After 9 months of follow up, epiphora decreased in 80% of the patients, while the amount of obstruction decreased to 50%. In patients with low grade anatomical obstruction the imporvement was 100% and with increasing degrees of obstruction, the success rate of this intervention decreased. Ophthalmic complications did not occur and nasal mucosal pallor was observed only in one patient. Intraductal mitomycin injection can reduce epiphora in adults with partial primary acquired nasolacrimal duct obstruction and is a safe method.